CordenPharma Group
Dr. Michael Quirmbach succeeded Dr. Riku Rautsola as the CEO and president of CordenPharma Group. To support the transition, Rautsola will become a senior advisor to the executive leadership team, which also includes Dr. Walter Kittl as COO, Heiko Serwe, CFO, and Dr. Esua Macniell, chief compliance officer.
“Since joining CordenPharma in 2014 I have had the great opportunity to contribute to building an industry-leading contract development and manufacturing organization,” said Quirmbach, who initially joined the company as the chief business officer.
“Our mission is clear,” he told us, “to provide superior support to leading pharmaceutical and biotechnology customers with delivered in full and on time products and services, keeping in mind the ultimate goal of improving the lives of the patients they serve, which are in critical need of the sophisticated medications we manufacture.”
In his new role, Quirmbach said he plans to continue growing CordenPharma “as a trusted, reliable and highly-respected CDMO by focusing on our integrated supply chain solution, supported with a clear, profitable growth strategy defined by our technology platforms.”
“Operational excellence, transparent and effective cost management and customer centricity will determine the foundation of our performance, while accelerated growth and sustained profit remain our ongoing objectives,” he added. “I look forward to this challenge and anticipate a promising future for CordenPharma in the years to come.”
Quirmbach previously has held management positions at companies including Siegfried, Dr. Reddy’s, and Solvias.
